Literature DB >> 7689528

Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients.

A S Lok1, D Chien, Q L Choo, T M Chan, E K Chiu, I K Cheng, M Houghton, G Kuo.   

Abstract

Some immunosuppressed patients with hepatitis C virus infection do not have detectable levels of antibody to hepatitis C virus on second-generation enzyme immunoassay. Antibodies to the envelope and nonstructural region 5 proteins have not been examined. Four groups of patients with hepatitis C virus infection were studied: (a) 20 immunocompetent patients, (b) 15 hemodialysis patients, (c) 17 kidney transplant recipients and (d) 3 acute leukemia patients who underwent bone marrow transplantation. Serum samples were tested for antibody to hepatitis C virus with a second-generation enzyme immunoassay and multi-antigen enzyme immunoassays and for hepatitis C virus RNA with a nested polymerase chain reaction assay. All the immunocompetent patients reacted to C25, C22 and C33C; 90% reacted to nonstructural region 5 antigen and 80% reacted to C100-3. Only 55% reacted against yeast-derived e1 and e2 antigens, but all reacted against vaccinia virus--expressed N e1 and e2 antigens, indicating that the envelope epitopes are conformational and glycosylated. Sixty-five percent to 90% of dialysis and kidney transplant patients reacted to C25, C22 and N e1 and e2, but only 12% to 60% reacted to C100-3, C33C and nonstructural region 5 antigen. Diminution or loss of reactivity to hepatitis C virus antigens was observed after kidney and bone marrow transplantation, with C25 and N e1 and e2 less affected. Our data suggest that incorporation of C25 and N e1 and e2 antigens in the assay for antibody to hepatitis C virus would improve the detection of hepatitis C virus infection in immunosuppressed patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689528

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  27 in total

Review 1.  Hepatitis C and liver transplantation.

Authors:  M Berenguer; T L Wright
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

2.  Use of a novel hepatitis C virus (HCV) major-epitope chimeric polypeptide for diagnosis of HCV infection.

Authors:  D Y Chien; P Arcangel; A Medina-Selby; D Coit; M Baumeister; S Nguyen; C George-Nascimento; A Gyenes; G Kuo; P Valenzuela
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

3.  Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs.

Authors:  M G Ghany; C Leissinger; R Lagier; R Sanchez-Pescador; A S Lok
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

4.  Anti-envelope antibodies in anti-hepatitis C virus (HCV) positive patients with and without liver disease.

Authors:  M Pirisi; P Ferroni; C Fabris; P Toniutto; G Soardo; D Vitulli; V Gasparini; E Bartoli
Journal:  Infection       Date:  1995 Jan-Feb       Impact factor: 3.553

5.  Definition of false-positive reactions in screening for hepatitis C virus antibodies.

Authors:  M Schröter; H H Feucht; P Schäfer; B Zöllner; S Polywka; R Laufs
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

Review 6.  Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease.

Authors:  Mahrukh Akbar Shaheen; Muhammad Idrees
Journal:  World J Hepatol       Date:  2015-03-27

7.  Quantitative detection of hepatitis C virus RNA by light cycler PCR and comparison with two different PCR assays.

Authors:  M Schröter; B Zöllner; P Schäfer; R Laufs; H H Feucht
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

8.  Design of novel conformational and genotype-specific antigens for improving sensitivity of immunoassays for hepatitis C virus-specific antibodies.

Authors:  Sansan Lin; Phillip Arcangel; Angelica Medina-Selby; Doris Coit; Philip Ng; Steve Nguyen; Colin McCoin; Alex Gyenes; Celine Hu; Laura Tandeske; Bruce Phelps; David Chien
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

9.  Immunosuppressive therapy and hepatitis C virus infection: the clinical course of liver disease.

Authors:  W H Grotz; T H Peters; H J Schlayer; G Kirste; H Berthold; H Felten; P J Schollmeyer; J W Rasenack
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

10.  Characteristics of hepatitis C virus infection in HIV-infected people.

Authors:  C L Cooper; A D Badley; J B Angel
Journal:  Can J Infect Dis       Date:  2001-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.